Guru P. Sonpavde MD
Genitourinary Oncology Director, Christopher K. Glanz Chair for Bladder Cancer Research, Assistant Director Phase I Clinical Research Unit, AdventHealth Cancer Institute, Orlando, FloridaDr. Guru Sonpavde, MD, is the Genitourinary Oncology Director at the AdventHealth Cancer Institute and the Christopher K. Glanz Chair for Bladder Cancer Research. He completed his fellowship in medical oncology and hematology at Indiana University. He leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to treat urological cancers, particularly bladder cancer. He is the national or international principal investigator on multiple clinical trials for bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.
Disclosures
Dr. Sonpavde reports the following:
-
Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV
-
Research Support: Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric, Kure it, NCI (R21)
- Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid)
- Data safety monitoring committee: Mereo
- Employment: Spouse employed by Myriad
- Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence
- Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS)
Recent Contributions to PracticeUpdate:
- The New Standard of Care in Post-Platinum and PD-L1 Inhibitor Setting of Metastatic Urothelial Carcinoma
- ESMO 2021: Recommendations From Dr. Guru Sonpavde for Urothelial Carcinoma
- Real-World Performance of Checkpoint Inhibitors Among Platinum-Ineligible Patients With Advanced Bladder Cancer
- Feladilimab Plus Pembrolizumab for Urothelial Carcinoma
- Durvalumab Plus Tremelimumab With Radiation for Muscle-Invasive Bladder Cancer
- Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma
- Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- Baseline Modified GPS Associated With Survival in Metastatic Urothelial Cell Carcinoma Treated With ICIs
- Clinical Insights From Outcomes in Patients With Upper vs Lower Urinary Tract Urothelial Carcinoma
- Enfortumab Vedotin vs Chemotherapy for Advanced Urothelial Carcinoma